In breast cancer, CD49f seems to be enriched in basal-like subtypes [63, 64], which is in concordance with our data from MDA-MB-231 showing the highest CD49f abundance, whereas its expression in luminal and HER2 subtypes was less pronounced. Here, ERBB2 is linked to breast carcinoma.